$CLX

CLOROX CO /DE/ (CLX): Results of Operations and Financial Condition

CLOROX CO /DE/ (CLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-pressreleasedatedaug.htm EX-99.1 Document Clorox Reports Q4 and FY26 Results, Provides FY27 Outlook Delivers Q4 results in line with expectations while advancing strategic investments OAKLAND, California, Aug. 3, 2026 — The Clorox Company (NYSE: CLX) today reporte

Original reporting
Published Aug 3, 2026, 8:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CLX
Neutral
medium confidence
Mentioned
$CLX
Relevance
8/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CLXNeutralMed
01

Why it matters

The filing frames FY26 results as in-line with expectations while highlighting margin pressure from acquisition inventory step-up and ERP transition lapping, alongside progress on integration and modernization. The company states FY27 starts from a stronger execution position in a challenging environment.

02

Market read

This is a primary earnings release via SEC 8-K with quantified quarterly performance and integration/ERP transition drivers, plus qualitative FY27 outlook.

03

What to watch

Gross margin decline is attributed to GOJO inventory step-up and ERP shipment comparisons; traders may over-focus on headline margin without separating one-time acquisition accounting and transition timing effects.

Relevance 8/10Novelty 8/10Timing: after-hours today, Aug. 3, 2026 filing of Q4 and FY26 results

Background

Clorox completed the GOJO Industries acquisition in April 2026 and also completed its U.S. ERP implementation as part of a multi-year digital transformation.

Company-level read

Ticker impact

$CLXNeutralMedium confidence
Context

Clorox reported Q4 and FY26 results on an 8-K, including net sales down 2% and gross margin down 520 bps, plus FY27 outlook language.

Expected impact

Near-term volatility likely as traders weigh margin compression and EPS decline against the acquisition integration and FY27 execution plan.

Evidence & confidence

The filing provides multiple quantified P&L drivers (sales, gross margin, EPS) and qualitative FY27 positioning, but the excerpt does not include specific FY27 numeric guidance.

Market effects

Signals ongoing cost volatility and integration-related margin headwinds for consumer staples hygiene and cleaning peers, especially those with recent acquisitions or system transitions.

Limited direct regional read-through beyond Clorox’s stated international segment FX benefit.

Moderate, as the story is company-specific but touches broader consumer value-seeking and commodity/manufacturing cost dynamics.

Counterpoint

Organic sales weakness is partly attributed to lapping ERP-related incremental shipments; excluding that effect, organic sales would have increased, which could reduce the perceived demand deterioration.

Key entities

  • The Clorox Company

    Reported Q4 and FY26 results and provided qualitative FY27 outlook in an SEC 8-K.

  • GOJO Industries, Inc.

    Acquired in April 2026; its integration and inventory step-up are cited as drivers of gross margin and EPS changes.

  • Linda Rendle

    CEO and Chair quoted on results being in line with expectations and on FY27 execution.

Related articles

$CLXMed

The Clorox Company Q4 2026 Earnings Call Summary

Clorox held its Q4 2026 earnings call, citing value-seeking consumer behavior and inflation pressures. Management said most categories have recovered from a prior cyberattack, with Litter still lagging. It highlighted GOJO acquisition synergies, fiscal 2027 assumptions including Brent at $90/bbl, inflation over $200M, and free cash flow of 11% to 13% of sales.

$CLXMedAI 8/10

Clorox fiscal 2027 outlook: inflation and value shoppers weigh

Clorox forecast a difficult fiscal 2027, citing inflation and consumers shifting to value. The company expects net sales up 13% to 14% for fiscal 2027, with about 9.5 points from its April 2026 GOJO Industries acquisition. Adjusted EPS is projected at $5.70 to $6.00, GAAP diluted EPS $5.41 to $5.71. Q4 revenue fell 2% to $1.95B; adjusted EPS was $1.66.

$CLXMedAI 8/10

Clorox forecasts upbeat annual sales as demand improves

Reuters reports Clorox (Pine-Sol maker) forecast fiscal 2027 net sales growth of 13% to 14%, above analysts’ 12.8% estimate, and adjusted EPS of $5.70 to $6 versus $5.97 expected. Q4 sales fell 2% to $1.95B but beat $1.90B. Gross margin dropped to 41.3%. Clorox cited improving demand amid a challenging cost and value-seeking environment.

$CLXMedAI 9/10

Clorox Announces Leadership Transition as CEO Linda Rendle Prepares to Exit

The Wall Street Journal reported May 28 that Clorox CEO Linda Rendle will step down for health reasons after more than two decades. Clorox said it has started a comprehensive search for a new chief executive, while Rendle will remain in her role. In a blog post, Rendle said she was diagnosed with early-stage breast cancer, is now cancer-free, and cited ongoing treatment side effects.

$KMBLow

Kimberly-Clark vs. The Clorox: Which Consumer Goods Stock Is a Better Buy in 2026?

The article compares Kimberly-Clark (KMB) and The Clorox Company (CLX) as consumer staples for 2026. Kimberly-Clark reported FY2025 revenue near $16.4B (down from $16.8B) and net income about $2.0B; Clorox reported FY2025 revenue near $7.1B (flat) and net income about $810M. It cites higher customer concentration for both (Walmart ~16% for KMB, ~27% for Clorox) and notes KMB is selling tissue operations to Suzano and has a potential $48B merger with Kenvue, while Clorox is recovering from a 2023